Monday Sessions – Day Two – October 19
Featuring symposia, panel discussions and debates, and Plenary Lectures led by renowned endocrinology specialists, surgeons, and other healthcare professionals and experts in thyroidology from around the world, the 15th International Thyroid Congress (ITC) will take place October 18-23, 2015 at the Walt Disney World Swan and Dolphin Resort in Lake Buena Vista, Florida. The ITC, held every five years, is a collaborative meeting of the four world thyroid associations: ATA (American Thyroid Association), Asia & Oceania Thyroid Association (AOTA), European Thyroid Association (ETA), and Latin American Thyroid Society (LATS).
On Monday, October 19, Day Two of ICT will feature a morning Plenary Lecture entitled “Advancing Individualized Medicine with Public-Private Partnerships,” delivered by Bill Chin, with an introduction by Robert Smallridge. Highlights of the Monday afternoon program include the ATA Memorial for John B. Stanbury and presentation of the Stanbury Pathophysiology Medal to Sheue-yann Cheng. The winner of the 2015 ATA Van Meter Award will also be announced, and the recipient will deliver the Van Meter Award Lecture.
A series of lively Discussions/Debates on Monday will focus on either clinical topics or basic/translational areas of research. Announced topics and participants for the Clinical Discussions/Debates include: “A Case-based Discussion of International Hypothyroidism Guidelines” with Jacqueline Jonklaas, Glaucia Mazeto and Salman Razvi; “Targeted Therapy for Thyroid Cancer: When and What? with Steven I. Sherman and Johannes W.A. Smit; “Unusual Thyroid Function Tests” with Mark Vanderpump (moderator), Inge Pedersen, Brian W. Kim, Shu Wang and Helton Estrela Ramos; “Management of Thyroid Storm” with Henry B. Burch and Tetsurou Satoh; and “Is There a Role for Long-Term Anti-Thyroid Drug Therapy?” with Stig Andersen and Douglas S. Ross.
Monday’s Basic/Translational Discussions/Debates will feature the following topics and participants: “TSHR Activation and Its Impact on Body Composition and Graves’ Orbitopathy” with Marian Ludgate and Lei Zhang; “Oxidative Stress on Thyrocytes” with Denise Pires de Carvalho and Xavier De Deken; “Immunity and Thyroid Cancer: Prospects for Immune Therapy” with Carolin Lisa Zhang and Mabel Ryder; “Interactions Between Hypothalamic Pituitary Thyroid Axis and Other Pituitary Dysfunction” with Ulla Feldt-Rasmussen and Salvatore Benvenga; and “Vertebrate Models for Study of TH Action” with Luca Persani and Yun-Bo Shi.
Symposiums on a range of hot topics chaired by world experts in their fields and featuring leading researchers and clinicians invited to share their knowledge and experiences will take place throughout the day on Monday. Beginning with the Early Riser Symposium, Chairs Ana O. Hoff and Laura Fugazzola have organized a session on “New Modalities in the Treatment of Medullary Thyroid Cancer (MTC)” featuring Rui M.B. Maciel speaking on Molecular Mechanisms of MTC; Rossella Elisei on Targeted Therapeutic Agents for MTC; Barbara Jarzab on Management of Side Effects of Long-Term Tyrosine Kinase Inhibitor Treatment; and Samuel Wells providing an Update on MTC Guidelines.
Morning symposia on Monday at ITC will include four parallel sessions. In the symposium called “Nontraditional TSHR Signaling” Chairs Basil Rapoport and Syed Morshed will highlight the work of presenters Terry F. Davies on Selective TSHR Signaling by TSHR Antibodies; Susanne E. Neumann on TSHR-Arrestin-1 Mediated Pathways; and Terry J. Smith on TSHR-IGF-1 Interactions.
“TR Alpha Mutations – Bench to Bedside,” led by Chairs V. Krishna Chatterjee and Marcel Meima, will include the following topics: Animal Models presented by Sheue-yann Cheng; Treatment of Animal Models by J.H. Duncan Bassett; Human Mutations by Carla Moran; and Treatment of Patients by Robin Peeters.
The symposium entitled “New Concepts in the Management of Thyroid Nodules“ organized by Chairs Stephanie Fish and Finn Bennedbaek, will feature presentations by Shuhang Xu on Epidemiology of Benign Thyroid Nodules; Arthur B. Schneider on Who Should Be Screened for Thyroid Nodules?; and Susan J. Mandel on Follow-Up of Benign Nodules?
Chairs Edna Kimura and Ileana Gabriela de Rubio will lead the symposium on “Thyroid Cancer – Translating Basic Science Discoveries to the Clinic,” with presenters James A. Fagin speaking on Redifferentiation of RAI-Refractory Thyroid Cancer; Yuri Nikiforov on Somatic Mutations Analysis for Molecular Diagnosis; and Sophie Leboulleux on Targeted Therapy.
ITC’s Monday afternoon program will feature another set of four fascinating symposia including “Clinical Utility of Anti-Thyroid Antibody Measurements” with Chairs Patricia de Fatima dos Santos Teixeira and Yuji Hiromatsu and presentations by Alex Stagnaro-Green on Pregnancy; Mario Rotondi on Hashimoto’s Thyroiditis; and Eijun Nishihara on Graves’ Disease.
Exploring the topic “TH Transport” will be session Chairs Ulrich Schweizer and Grant Anderson, with focused presentations on Animal Models of TH Transporter Disease by Heike Heuer; Therapeutic Studies Using Animal Models by Alexandra Dumitrescu; Human TH Transporter Mutations by Theo J. Visser; and Clinical Trials in Allan Herndon Dudley Syndrome by Edward Visser.
The Monday afternoon symposia at ITC will include a session entitled “T4/T3 Combination Therapy for Hypothyroidism.” Joining Chairs Elizabeth Mcaninch and Birte Nygaard are presenters Colin M. Dayan discussing Do Patients Prefer T4/T3 Therapy, and Why?; Francesco Celi speaking on What is the Mechanism for Enhanced Weight Loss with T3?; and Anne R. Cappola focusing on Risks/Safety of Combination Therapy. The symposium “Prognostic Assessment of Thyroid Cancer” led by Chairs Mario Vaisman and Duncan Topliss targets three key areas: Functional Imaging, to be discussed by Byeong-Cheol Ahn; Clinical Risk Stratification, presented by Furio Pacini; and Real Time Prognostication, explored by R. Michael Tuttle.
The ITC Program Organizing Committee (POC) has invited renowned international thyroid experts for every symposium and discussion/debate. The POC has designed this ITC to highlight and involve young investigators from around the world. The American Thyroid Association (ATA) will continue to promote the E. Chester Ridgway Trainee Conference with a unique and focused track for trainees; participation includes accommodations and complimentary registration for a limited number of applicants who are first authors on accepted abstracts. The four international thyroid associations combine their efforts to contribute to this one of a kind, state-of-the-science experience! Don’t miss this “top of the mark” collegial event.
Hosted by the ATA, the ITC will bring together the international community of thyroid researchers and clinicians to present and discuss the latest advances and controversies in thyroidology. The ATA and its annual meetings are well known and well regarded by all those devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health.
###
The American Thyroid Association (ATA) is the leading worldwide organization dedicated to the advancement, understanding, prevention, diagnosis, and treatment of thyroid disorders and thyroid cancer. ATA is an international membership medical society with over 1,700 members from 43 countries around the world. Celebrating its 92nd anniversary, the ATA delivers its mission — of being devoted to thyroid biology and to the prevention and treatment of thyroid disease through excellence in research, clinical care, education, and public health — through several key endeavors: the publication of highly regarded professional journals, Thyroid, Clinical Thyroidology, and VideoEndocrinology; annual scientific meetings; biennial clinical and research symposia; research grant programs for young investigators, support of online professional, public and patient educational programs; and the development of guidelines for clinical management of thyroid disease and thyroid cancer. The ATA promotes thyroid awareness and information through its online Clinical Thyroidology for the Public (distributed free of charge to over 11,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA website serves as the clinical resource for patients and the public who look for reliable information on the Internet. Every fifth year, the American Thyroid Association joins with the Latin American Thyroid Society, the European Thyroid Association, and the Asia and Oceania Thyroid Association to co-sponsor the International Thyroid Congress (ITC). This year the ITC is hosted by the American Thyroid Association at the Walt Disney World Swan and Dolphin Resort. More information about the 15th ITC can be found at http://www.thyroid.org/itc2015/.
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.